ResearcherWhitehead Institute for Biomedical ResearchNo recent work listed

Mohammad Rashidian

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3708-0038; OpenAlex author ID A5077522096. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2015: 1 paper

Papers 1

The use of 18F-2-fluorodeoxyglucose (FDG) to label antibody fragments for immuno-PET of pancreatic cancer. Co-author DOI 10.1021/acscentsci.5b00121 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Michael Lawrence Dougan · 1 shared paper, 2015 · strength 0.05
- Paper The use of 18F-2-fluorodeoxyglucose (FDG) to label antibody fragments for immuno-PET of pancreatic cancer. DOI 10.1021/acscentsci.5b00121 ↗
Hidde L. Ploegh · 1 shared paper, 2015 · strength 0.05
- Paper The use of 18F-2-fluorodeoxyglucose (FDG) to label antibody fragments for immuno-PET of pancreatic cancer. DOI 10.1021/acscentsci.5b00121 ↗
Edmund J. Keliher · 1 shared paper, 2015 · strength 0.05
- Paper The use of 18F-2-fluorodeoxyglucose (FDG) to label antibody fragments for immuno-PET of pancreatic cancer. DOI 10.1021/acscentsci.5b00121 ↗
Ralph Weissleder · 1 shared paper, 2015 · strength 0.05
- Paper The use of 18F-2-fluorodeoxyglucose (FDG) to label antibody fragments for immuno-PET of pancreatic cancer. DOI 10.1021/acscentsci.5b00121 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.